Cleo Diagnostics (ASX:COV) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Days Payable?

Cleo Diagnostics's average Accounts Payable for the six months ended in Dec. 2023 was A$0.31 Mil. Cleo Diagnostics's Cost of Goods Sold for the six months ended in Dec. 2023 was A$0.00 Mil.

The historical rank and industry rank for Cleo Diagnostics's Days Payable or its related term are showing as below:

ASX:COV's Days Payable is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 72.55
* Ranked among companies with meaningful Days Payable only.

Cleo Diagnostics's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Cleo Diagnostics Days Payable Historical Data

The historical data trend for Cleo Diagnostics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Days Payable Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Days Payable

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Days Payable	-	-	-

Competitive Comparison of Cleo Diagnostics's Days Payable

For the Medical Devices subindustry, Cleo Diagnostics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics's Days Payable Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Days Payable distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Days Payable falls into.

Cleo Diagnostics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Cleo Diagnostics's Days Payable for the fiscal year that ended in Jun. 2023 is calculated as

	Days Payable (A: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: . 20 )	+	Accounts Payable (A: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2023 )	*	Days in Period
=	( (	+	0.417)	/	1 )	/	0	*	365
=	0.417					/	0	*	365
=	N/A

Cleo Diagnostics's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0.417	+	0.196)	/	2 )	/	0	*	365 / 2
=	0.3065					/	0	*	365 / 2
=	N/A

Cleo Diagnostics Days Payable Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines